|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recent molecular studies of expression of serotonin, GABA and CRH receptors in various brain regions have demonstrated that molecular factors may contribute to the development of depressive disorder and suicide behaviour.
|
23110080 |
2012 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Serotonin, norepinephrine, dopamine, and trace amines, such as the "endogenous amphetamine" phenylethylamine, are increased in brain, which leads to changes in neuroplasticity by e.g. increased neurotrophic growth factors and translates to reduced stress-induced hypersecretion of corticotropin releasing factor (CRF) and positive testing in animal studies of depression.
|
28655495 |
2017 |
|
Depressive disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recently, two studies have reported an interaction between childhood abuse and the TAT-haplotype of the CRH-Receptor Gene (CRHR1) connecting childhood adversities and genetic susceptibility to adult depression.
|
20957648 |
2010 |
|
Depressive disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Numerous reports suggest that alterations in CRF function contribute to the pathogenesis of depression.
|
16122764 |
2006 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
Correlation analysis indicated that the alteration of multiple CRF-controlling receptors is highly correlated with depression-related behaviors of rats in the forced swimming test.
|
25578258 |
2015 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
The corticotropin releasing hormone (CRH) and the CRH receptor 1 (CRHR1) have been implicated in the link between early life adversity and adult anxiety and depression, with rodent studies identifying the very early postnatal period as highly susceptible to this programming.
|
24630468 |
2014 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Hyperactivity of corticotropin-releasing factor (CRF) neurons in the paraventricular nucleus (PVN) of the hypothalamus is a prominent feature in depression and may be important in the etiology of this disease.
|
18427561 |
2008 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Corticotropin-releasing hormone (CRH), produced by MCs, has been found in microglial cells where it regulates immune cells and contributes to the pathogenesis of neurodegenerative diseases including depression.
|
29907890 |
2018 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
Because dysregulation of CRH expression occurs in stress-related disorders including depression, a full understanding of the complex regulation of this gene is important in both health and disease.
|
23768074 |
2014 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
The following search items were used: "hypothalamic-pituitary-adrenal" OR "HPA" OR "cortisol" OR "corticotropin releasing hormone" OR "corticotropin releasing factor" OR "glucocorticoid*" OR "adrenocorticotropic hormone" OR "ACTH" AND "atypical depression" OR "non-atypical depression" OR "melancholic depression" OR "non-melancholic depression" OR "endogenous depression" OR "endogenomorphic depression" OR "non-endogenous depression".
|
29150144 |
2018 |
|
Depressive disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we demonstrated that chronic FS stress (CFSS) could activate corticotropin-releasing factor (CRF)/CRF receptor type 1 (CRFR1) signaling in the BLA, and blockade of CRF/CRFR1 signaling by intra-BLA injection of NBI27914 (NBI), a selective CRFR1 antagonist, could prevent the CFSS-induced depressive-like behaviors in rats, indicating that activation of CRF/CRFR1 signaling in the BLA is required for CFSS-induced depression.
|
29080675 |
2018 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
A concatenation of findings from preclinical and clinical studies support a preeminent function for the corticotropin-releasing factor (CRF) system in mediating the physiological response to external stressors and in the pathophysiology of anxiety and depression.
|
20010888 |
2010 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, elevated CRF in cerebrospinal fluid is observed in mood and anxiety disorder patients, suggesting that CRF is also being overproduced from extrahypothalamic sources such as the central amygdala (CeA) and overactivity of the amygdala in neuroimaging studies is a consistent finding in anxiety and depression patients.
|
21616602 |
2012 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
Association of glucocorticoid and type 1 corticotropin-releasing hormone receptors gene variants and risk for depression during pregnancy and post-partum.
|
23726670 |
2013 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Indeed, animal studies have shown that vulnerability to depressive-like behaviors involve mechanisms similar to those associated with human depression (e.g., altered serotonin, corticotropin releasing hormone and their receptors, growth factors), and that the effects of stressors are influenced by previous stressor experiences, particularly those encountered early in life.
|
18423590 |
2008 |
|
Depressive disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Early-life adversity, such as physical or sexual abuse during childhood, results in long-lasting changes in the CRF-mediated stress response and a greatly increased risk of depression in genetically predisposed persons.
|
16124836 |
2005 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
TC-IBS showed a pronounced depression phenotype with increased corticotropin-releasing hormone receptor (CRHR)1 and CRHR2 expression at the frontal cortex and increased serum ACTH concentration.
|
31570003 |
2019 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Preclinical studies have shown that dysregulation of the corticotropin releasing factor (CRF) neurotransmission has been implicated in stress-related psychopathologies such as depression and anxiety, and may affect alcohol consumption.
|
29118713 |
2017 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data indicate that CRF receptor antagonists may be useful for the treatment of the disease states where CRF is elevated such as anxiety and depression, anorexia nervosa and stroke and that ligand inhibitors of CRF-BP may be used to elevate brain levels of 'free' urocortin and other CRF-related peptides.
|
9118350 |
1996 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Corticotropin-releasing factor binds with high affinity to CRF receptor 1 (CRFR1) and is implicated in stress-related mood disorders such as anxiety and depression.
|
30499109 |
2019 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Corticotropin-releasing factor (CRF) regulates stress responses, and aberrant CRF signals are associated with depressive disorders.
|
31017816 |
2019 |
|
Depressive disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association of glucocorticoid and type 1 corticotropin-releasing hormone receptors gene variants and risk for depression during pregnancy and post-partum.
|
23726670 |
2013 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
CRF overproduction has been implicated in affective disorders, such as depression and anorexia nervosa, and may lead to Cushing's syndrome.
|
1597149 |
1992 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Specifically described are sex differences in receptors for the stress neuropeptide, corticotropin-releasing factor (CRF), that render the locus coeruleus arousal system of females more vulnerable to stress and less adaptable to CRF hypersecretion, a condition found in patients with PTSD and depression.
|
30022063 |
2019 |
|
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Dex/CRH test is one of the most reliable neuroendocrine function tests for hypothalamic-pituitary-adrenocortical (HPA) system dysregulation in depression.
|
12147330 |
2002 |